Current Cancer Drug Targets, Volume 6 - Number 6

Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers

, 6(6): 455 - 489

D. N. Waterhouse, K. A. Gelmon, R. Klasa, K. Chi, D. Huntsman, E. Ramsay, E. Wasan, L. Edwards, C. Tucker, J. Zastre, Y. Z. Zhang, D. Yapp, W. Dragowska, S. Dedha and M. B. Bally

DOI: 10.2174/156800906778194586

Synthetic Glycopeptides from the Mucin Family as Potential Tools in Cancer Immunotherapy

, 6(6): 491 - 517

Torsten Becker, Sebastian Dziadek, Sven Wittrock and Horst Kunz

DOI: 10.2174/156800906778194577

Protein Tyrosine Phosphatases, New Targets for Cancer Therapy

, 6(6): 519 - 532

David Easty, William Gallagher and D. C. Bennett

DOI: 10.2174/156800906778194603

Knowledge of Epigenetic Influence for Prostate Cancer Therapy

, 6(6): 533 - 551

Masatoshi Watanabe, Akimitsu Takagi, Takeshi Matsuzaki, Daisuke Kami, Minoru Toyota, Yoshifumi Hirokawa and Taizo Shiraishi

DOI: 10.2174/156800906778194568

Implications of Somatic Mutations in the AML1/RUNX1 Gene in Myelodysplastic Syndrome (MDS): Future Molecular Therapeutic Directions for MDS

, 6(6): 553 - 563

Hironori Harada, Yuka Harada and Akiro Kimura

DOI: 10.2174/156800906778194595

Webmaster Contact:
Copyright © 2018 Bentham Science